Boston Scientific Corporation (BSX) earnings on October 28, 2026

Before the market opens Q3 2026

More Boston Scientific Corporation earnings

Prior outlook: Optimistic Outcome: Missed

Boston Scientific shares fell sharply after earnings, dropping as much as 14.34% intraday before closing down 5.84%. Concerns about a lower outlook weighed on the stock.

BSX price around the earnings

42.43

Change: -5.8%

2026-10-28, 20:00 UTC

Start of the measured window End of the measured window
38.70 40.96 43.22 45.48 45.06
Price series around the eventClosing price per minute from before the event to the end of the measured window.
October 28, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Missed

Thesis published
Results released

The price setup points optimistic and outweighed more cautious positioning: recent gains and stronger performance versus the broader market support the outlook, even though analyst price targets sit below the current price and crowd optimism is extreme.

Context analyzed before publication

Playbook
Recent price performance and expected company growth remain favorable, while mixed analyst actions and negative post-earnings reactions keep the backdrop uneven.
Trend
Analyst confidence improved sharply in recent sessions

Analysts

Drivers

  • Analysts Negative

    The average analyst price target of $58 is below the current $64.60, and Stifel recently lowered its target to $55, showing caution even though most analysts point to an optimistic scenario.

Evidence

Analyst consensus
Buy
Consensus average (1-5)
1.6
Analysts covering the stock
28
Average price target
57.82
Lowest price target
44
Highest price target
78
Upside to price target
28.3%
Quarterly earnings growth
13.8%
Revenue growth
7.5%
Forward EPS
3.38
Trailing EPS
2.47
Analyst moves in the last 60 days
8
  • Strong buy: 6
  • Buy: 18
  • Hold: 6
  • Sell: 0
  • Strong sell: 0
Strong buy
6
Buy
18
Hold
6
Sell
0
Strong sell
0
  • October 26, 2026 · Stifel: Maintains rating (Buy → Buy)
  • October 14, 2026 · Truist Securities: Maintains rating (Buy → Buy)
  • October 7, 2026 · Barclays: Initiates coverage (Equal-Weight)
  • October 5, 2026 · Citigroup: Maintains rating (Neutral → Neutral)
  • September 24, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
  • September 21, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
  • September 17, 2026 · Citigroup: Downgrades rating (Buy → Neutral)
  • September 9, 2026 · BTIG: Maintains rating (Buy → Buy)

News and sentiment

Drivers

  • News & sentiment Negative

    Retail sentiment is extremely crowded on the optimistic side, at 85.71% in a small sample, which conflicts with the pessimistic scenario indicated by analyst price targets. The overall scenario remains optimistic.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
Messages
30

Technicals

Drivers

  • Technical Positive

    Trend strength is positive over 14 days (+4.08%) and 30 days (+2.64%), and price performance has exceeded the S&P 500 by 2.85%, supporting a constructive near-term outlook.

Evidence

Price when the context was analyzed
45.08
Average true range (ATR)
2.5%
Distance to 52-week high
-57.1%
14-day change (14d)
+4.1%
30-day change (32d)
+2.6%
30-day relative strength
+2.9%
SPY change (32d)
-0.2%
Nearest support
44.8
Distance to nearest support
0.6%
Nearest resistance
45.1
Distance to nearest resistance
0.1%
Volume accumulation ratio (14d / 46d)
0.79
  • Mid: 44.8 (0.6% away, 0.25 ATR, 14 touches)
  • Mid: 44.38 (1.6% away, 0.63 ATR, 32 touches)
  • Major: 43.93 (2.6% away, 1.03 ATR, 43 touches)
  • Mid: 45.1 (0.1% away, 0.02 ATR, 36 touches)
  • Mid: 45.42 (0.8% away, 0.31 ATR, 13 touches)
  • Mid: 45.78 (1.6% away, 0.64 ATR, 22 touches)

Trends

Evidence

Average earnings surprise
+3.3%
  • July 29, 2026: actual EPS 0.86 vs estimate 0.83 (surprise +3.9%)
  • April 22, 2026: actual EPS 0.8 vs estimate 0.79 (surprise +1.6%)
  • February 4, 2026: actual EPS 0.8 vs estimate 0.78 (surprise +2.4%)
  • October 22, 2025: actual EPS 0.75 vs estimate 0.71 (surprise +5.1%)

Expected move

Drivers

  • Past earnings Negative

    The last two earnings reports were followed by price drops of 11.5% on February 4, 2026, and 7.5% on July 29, 2026. This recurring reaction occurred despite better-than-expected earnings per share, although the scenario remains optimistic.

Implied move
+7.2%
Source
Options chain

Reactions over its last 21 earnings

Median move
2.8%
75th percentile move
4.4%
90th percentile move
6.2%
Up / down moves
13 / 8
Average up move
+3.6%
Average down move
-3.3%

Monitoring and close

What Boston Scientific Corporation reported

Status
Finished
Actual EPS0.73
EPS estimate0.72
EPS surprise+1.4%
Revenue$5,138 million
Revenue estimate$5,046 million
Revenue surprise+1.8%

Boston Scientific cut its 2026 guidance for the third time following a cybersecurity incident. Third-quarter revenue rose and beat estimates, but margins weakened and shares fell.

Sources (30)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating -12.9% pre-market, a move 5x the stock's usual reaction (about 3%). The figures overturn the prior optimistic scenario. Across our market history, in the 458 similar cases the close held that direction 94% of the time.

How the stock reacted

Outcome
Missed
Consolidated
-5.8%
Max favorable move (MFE)
0.9%
Max adverse move (MAE)
14.3%